[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530024":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":26,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":26,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":26,"enrollmentInfo":63,"targetDuration":26,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":26,"overallStatus":36,"whyStopped":26,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Rambam Health Care Campus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Immediate oxytocin","EXPERIMENTAL","This arm will receive oxytocin when entering 2nd stage (full dilation)",[13],"Drug: Oxytocin",{"label":15,"type":6,"description":16,"interventionNames":17},"Delayed oxytocin","This arm will receive oxytocin one hour after entering 2nd stage (full dilation)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Oxytocin","Native oxytocin analog",[15,9],[25],"Pitocin",null,[28],{"name":29,"role":30,"phone":31,"phoneExt":26,"email":32},"Gal Bachar, MD","CONTACT","+97247771449","g_bachar@rambam.health.gov.il",[34],{"facility":35,"status":36,"city":37,"state":26,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Rambam medical health campus","RECRUITING","Haifa","31999","Israel","IL",{"type":42,"coordinates":43},"Point",[44,45],34.99928,32.81303,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":26,"phoneExt":26,"email":26},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Gal Bachar MD","Doctor of OBGYN","100530024","time-of-oxytocin-initiation-at-2nd-stage-of-labor-and-adverse-outcomes-100530024",false,"NCT06181396","Time of Oxytocin Initiation at 2nd Stage of Labor and Adverse Outcomes","Association Between Time of Oxytocin Initiation at 2nd Stage of Labor and Adverse Outcomes","Inclusion Criteria:\n\n1. Singleton pregnancy\n2. Maternal age ≥ 18 years' old\n3. Oxytocin administration initiated or renewed during second stage of labor\n\nExclusion Criteria:\n\n1. Maternal age \\\u003C 18 years' old\n2. Multiple gestation pregnancy\n3. Known fetal malformations\n4. Uterine scar",true,"FEMALE","18 Years",{"count":64,"type":65},120,"ESTIMATED","INTERVENTIONAL",[68],"NA","Early oxytocin administration at the 2nd stage of labor is associated with a higher rate of vaginal delivery, shorter second stage duration, and fewer adverse maternal and neonatal outcomes.",[71,72],"Delivery Complication","Cesarean Delivery Affecting Fetus","2023-12-22",{"date":75,"type":76},"2023-12-26","ACTUAL",{"date":78,"type":76},"2023-10-01",{"date":80,"type":65},"2026-10",{"name":5,"class":6},1]